The p53 breast cancer tissue biomarker in Indian women

Vinayak W Patil1, Mukund B Tayade2, Sangeeta A Pingale1, Shubhangi M Dalvi1, Rajesh B Rajekar1, Hemkant M Deshmukh1, Shital D Patil1, Rajeev Singhai11Department of Biochemistry, 2Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, IndiaBackground: Combination...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/978c05e2eaf34d86b6a747c5fc8ffe7a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:978c05e2eaf34d86b6a747c5fc8ffe7a
record_format	dspace
spelling	oai:doaj.org-article:978c05e2eaf34d86b6a747c5fc8ffe7a2021-12-02T02:03:08ZThe p53 breast cancer tissue biomarker in Indian women1179-1314https://doaj.org/article/978c05e2eaf34d86b6a747c5fc8ffe7a2011-08-01T00:00:00Zhttp://www.dovepress.com/the-p53-breast-cancer-tissue-biomarker-in-indian-women-a8064https://doaj.org/toc/1179-1314Vinayak W Patil1, Mukund B Tayade2, Sangeeta A Pingale1, Shubhangi M Dalvi1, Rajesh B Rajekar1, Hemkant M Deshmukh1, Shital D Patil1, Rajeev Singhai11Department of Biochemistry, 2Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, IndiaBackground: Combination chemotherapy is highly effective in locally advanced breast cancer. A negative expression of biomarker p53 indicates a higher chance of responding to this regimen. Patients&#39; p53 status may be used as a biological cancer marker to identify those who would benefit from more aggressive treatments.Aims: The role of p53 in modulating apoptosis has suggested that it may affect the efficacy of anticancer agents. p53 alterations in 80 patients with locally advanced breast cancer IIIB undergoing neoadjuvant chemotherapy were prospectively evaluated.Materials and methods: Patients received three cycles of paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression, using immunohistochemistry and DNA sequencing.Results: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of 25 patients who obtained a complete clinical response, only two were classified as p53-positive (P = 0.004, &chi;2). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, &chi;2).Conclusion: Immunohistochemical (IHC) analysis has been shown to be a prognostic factor for patients with breast cancer in India. Paclitaxel is one of the most promising anticancer agents for the therapy of breast cancer, where it has also shown activity in tumors resistant to doxorubicin.Keywords: breast cancer, doxorubicin, p53, paclitaxel, cancer tissue biomarkers, neoadjuvant chemotherapy, immunohistochemistry, infiltrating duct cancerPatil VTayade MPingale SDalvi SRajekar RDeshmukh HPatil SSinghai RDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 71-78 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Patil V Tayade M Pingale S Dalvi S Rajekar R Deshmukh H Patil S Singhai R The p53 breast cancer tissue biomarker in Indian women
description	Vinayak W Patil1, Mukund B Tayade2, Sangeeta A Pingale1, Shubhangi M Dalvi1, Rajesh B Rajekar1, Hemkant M Deshmukh1, Shital D Patil1, Rajeev Singhai11Department of Biochemistry, 2Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, IndiaBackground: Combination chemotherapy is highly effective in locally advanced breast cancer. A negative expression of biomarker p53 indicates a higher chance of responding to this regimen. Patients&#39; p53 status may be used as a biological cancer marker to identify those who would benefit from more aggressive treatments.Aims: The role of p53 in modulating apoptosis has suggested that it may affect the efficacy of anticancer agents. p53 alterations in 80 patients with locally advanced breast cancer IIIB undergoing neoadjuvant chemotherapy were prospectively evaluated.Materials and methods: Patients received three cycles of paclitaxel (175 mg/m2) and doxorubicin (60 mg/m2) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression, using immunohistochemistry and DNA sequencing.Results: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of 25 patients who obtained a complete clinical response, only two were classified as p53-positive (P = 0.004, &chi;2). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, &chi;2).Conclusion: Immunohistochemical (IHC) analysis has been shown to be a prognostic factor for patients with breast cancer in India. Paclitaxel is one of the most promising anticancer agents for the therapy of breast cancer, where it has also shown activity in tumors resistant to doxorubicin.Keywords: breast cancer, doxorubicin, p53, paclitaxel, cancer tissue biomarkers, neoadjuvant chemotherapy, immunohistochemistry, infiltrating duct cancer
format	article
author	Patil V Tayade M Pingale S Dalvi S Rajekar R Deshmukh H Patil S Singhai R
author_facet	Patil V Tayade M Pingale S Dalvi S Rajekar R Deshmukh H Patil S Singhai R
author_sort	Patil V
title	The p53 breast cancer tissue biomarker in Indian women
title_short	The p53 breast cancer tissue biomarker in Indian women
title_full	The p53 breast cancer tissue biomarker in Indian women
title_fullStr	The p53 breast cancer tissue biomarker in Indian women
title_full_unstemmed	The p53 breast cancer tissue biomarker in Indian women
title_sort	p53 breast cancer tissue biomarker in indian women
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/978c05e2eaf34d86b6a747c5fc8ffe7a
work_keys_str_mv	AT patilv thep53breastcancertissuebiomarkerinindianwomen AT tayadem thep53breastcancertissuebiomarkerinindianwomen AT pingales thep53breastcancertissuebiomarkerinindianwomen AT dalvis thep53breastcancertissuebiomarkerinindianwomen AT rajekarr thep53breastcancertissuebiomarkerinindianwomen AT deshmukhh thep53breastcancertissuebiomarkerinindianwomen AT patils thep53breastcancertissuebiomarkerinindianwomen AT singhair thep53breastcancertissuebiomarkerinindianwomen AT patilv p53breastcancertissuebiomarkerinindianwomen AT tayadem p53breastcancertissuebiomarkerinindianwomen AT pingales p53breastcancertissuebiomarkerinindianwomen AT dalvis p53breastcancertissuebiomarkerinindianwomen AT rajekarr p53breastcancertissuebiomarkerinindianwomen AT deshmukhh p53breastcancertissuebiomarkerinindianwomen AT patils p53breastcancertissuebiomarkerinindianwomen AT singhair p53breastcancertissuebiomarkerinindianwomen
_version_	1718402721391837184

The p53 breast cancer tissue biomarker in Indian women

Ejemplares similares